Bioavailability Evaluation of curQ+ Curcumin Formulation

Bioavailability Clinical Trial

Official title:

Bioavailability Evaluation of a Micellar Curcumin Formulation (curQ+) Versus 95% Curcumin Extract in Healthy Individuals

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06177483
• Other study ID #: ESM-CLN#2023T02
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 1, 2024
• Est. completion date: July 30, 2024

Study information

• Verified date: February 2024
• Source: ESM Technologies, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is intended to evaluate how significantly a proprietary curcumin formulation (curQ+®) results in greater bioavailability compared to 95% curcumin extract over a 6-hour time period following a single oral dose in healthy men & women.

Description:

This study is intended to evaluate how significantly a proprietary curcumin formulation (curQ+®) results in greater bioavailability compared to 95% curcumin extract over a 6-hour time period following a single oral dose in healthy men & women. Bioavailability will be based upon producing the greatest plasma curcumin concentration (AUC). Secondarily, this study is intended to evaluate the safety and tolerability of the curQ+® curcumin formulation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. completion date: July 30, 2024
• Est. primary completion date: April 5, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or Female subjects must be 18-75 years of age at the time of Screening.

2. Subjects must be willing to refrain from consuming the spice turmeric or any dietary supplements containing turmeric or curcumin (except for the study products) throughout the entire study and for 14 days prior to screening.

3. Subjects must be available for and willing to attend all evaluation visits.

4. Subjects must be able and willing to give informed consent.

5. Subjects participating in prior studies evaluating curQ+® or curcumin can participate in the present study so long as they are not currently taking a curcumin-containing supplement (including turmeric) and have not done so for 14 days prior to screening.

Exclusion Criteria:

1. Subject is currently receiving therapy with remission-inducing drugs (i.e. methotrexate, TNF biologics, etc.), immunosuppressive drugs (i.e. corticosteroids, transplantation medications, etc.).

2. Subjects must not have taken turmeric- or curcumin-containing dietary supplements within 14 days prior to screening evaluation.

3. Subject has been diagnosed with any clinically significant confounding metabolic disease or condition that would interfere with the study evaluation, as judged by the clinical investigator (slow or fast metabolism resulting from hypo- or hyper-thyroidism, Cushing's Syndrome, Diabetes (except for fully resolved gestational diabetes), etc.) or any conditions that would affect absorption in the GI tract (i.e. inflammatory bowel disease, celiac disease, Behçet's Syndrome, systemic sclerosis, etc.).

4. Subject has known allergy to any of the investigational products, including but not limited to turmeric, curcumin, coconut or coconut oil, and sunflower oil. If any subject becomes sensitive during the study, they will immediately be excluded from continuing in the study.

5. Subject's body weight is greater than 300 pounds (136.1 kg) at the time of Screening.

6. Subject is involved in any other research study involving an investigational product (drug, device or biologic) or a new application of an approved product, within 30 days of the first baseline evaluation.

7. Pregnant and/or breastfeeding women, or women who intend to become pregnant during the course of the study.

Related Conditions & MeSH terms

• Bioavailability

Intervention

Dietary Supplement:
• 95% curcumin extract powder
95% curcumin extract powder
• curQ+ curcumin formulation
curQ+ curcumin formulation

Locations

Country	Name	City	State
United States	University of Texas Health Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
ESM Technologies, LLC	The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absorption of curcumin	difference between the absorption of curQ+ versus 95% curcumin powder	6 hours